Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Research & Development (2016 - 2025)

Editas Medicine (EDIT) has disclosed Research & Development for 11 consecutive years, with $19.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 58.49% to $19.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $111.2 million, a 49.52% decrease, with the full-year FY2024 number at $199.2 million, up 12.16% from a year prior.
  • Research & Development was $19.8 million for Q3 2025 at Editas Medicine, up from $16.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $69.6 million in Q4 2023 to a low of $16.2 million in Q2 2025.
  • A 5-year average of $39.8 million and a median of $40.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 82.04% in 2024, then plummeted 70.15% in 2025.
  • Editas Medicine's Research & Development stood at $37.6 million in 2021, then soared by 38.47% to $52.0 million in 2022, then surged by 33.77% to $69.6 million in 2023, then plummeted by 30.11% to $48.6 million in 2024, then tumbled by 59.32% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Research & Development are $19.8 million (Q3 2025), $16.2 million (Q2 2025), and $26.6 million (Q1 2025).